Zobrazeno 1 - 10
of 26
pro vyhledávání: '"M R Litzow"'
Autor:
K. H. Begna, X. Xu, N. Gangat, H. Alkhateeb, M. M. Patnaik, A. Al-Kali, M. A. Elliott, W. J. Hogan, M. R. Litzow, C. C. Hook, A. P. Wolanskyj-Spinner, A. Mangaonkar, R. He, A. Pardanani, M. Shah, R. P. Ketterling, A. Tefferi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-4 (2022)
Externí odkaz:
https://doaj.org/article/b2b5bce960224cf2bc1e809d5f6873fb
Autor:
K. H. Begna, J. Kittur, N. Gangat, H. Alkhateeb, M. S. Patnaik, A. Al-Kali, M. A. Elliott, W. J. Hogan, M. R. Litzow, A. Pardanani, C. A. Hanson, R. P. Ketterling, A. Tefferi
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-8 (2022)
Abstract We sought to appraise the value of overall response and salvage chemotherapy, inclusive of allogeneic hematopoietic stem cell transplant (AHSCT), in primary refractory acute myeloid leukemia (prAML). For establishing consistency in clinical
Externí odkaz:
https://doaj.org/article/4883604e468f479bbb604b57a39becff
Autor:
A, Dispenzieri, A, D'Souza, M A, Gertz, K, Laumann, G, Wiseman, M Q, Lacy, B, LaPlant, F, Buadi, S R, Hayman, S K, Kumar, D, Dingli, W J, Hogan, S M, Ansell, D A, Gastineau, D J, Inwards, I N, Micallef, L F, Porrata, P B, Johnston, M R, Litzow, T E, Witzig
Publikováno v:
Bone marrow transplantation. 52(10)
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (
Autor:
Jean E. Sanders, C. D. Buckner, Oliver W. Press, Gary Schoch, Stephen W. Crawford, L D Fisher, J E Anderson, Finn Bo Petersen, F R Appelbaum, M R Litzow
Publikováno v:
Journal of Clinical Oncology. 11:2342-2350
PURPOSE To analyze results of 127 patients undergoing myeloablative therapy followed by marrow transplantation for relapsed or refractory Hodgkin's disease. PATIENTS AND METHODS Twenty-three patients had primary refractory disease, 34 were in early f
Autor:
E. H. Nichols, M. R. Litzow
Publikováno v:
MD Conference Express. 13:30-31
Publikováno v:
Croatian medical journal. 42(4)
Dendritic cells are pivotal regulators of immune reactivity and immune tolerance. The observation that dendritic cells can recruit naive T-cells has invigorated cancer immunology and stimulated clinical trials of dendritic cells in immunotherapy. How
Autor:
A, Palmas, A, Tefferi, J L, Myers, J P, Scott, S J, Swensen, M G, Chen, D A, Gastineau, M A, Gertz, D J, Inwards, M Q, Lacy, M R, Litzow
Publikováno v:
British journal of haematology. 100(4)
We examined the incidence and clinical outcome of late-onset noninfectious pulmonary complications (LONIPC) in a series of 234 patients who underwent allogeneic bone marrow transplantation at our institution between April 1982 and October 1996. The 1
Publikováno v:
Blood. 77(11)
Human hematopoietic colony-forming cells (CFC) express the CD34 antigen (CD34+) as well as differentiation antigens such as CD33 and HLA-DR. CD34+ cells that do not express these latter differentiation antigens have been shown to contain few CFC in d
Publikováno v:
J. Chem. Soc. A. :2262-2267
Appearance potentials for the ions M2Me3+ of the title compounds have been measured, and used in combination with accurate thermochemical data to obtain the corresponding metal–metal bond dissociation energies. For the bonds M1–M2, D(W–M2) > D(
Publikováno v:
J. Chem. Soc. A. :383-385
Redistribution equilibria: ⅔BX3+⅓BY3⇌ BX2Y and ⅓BX3+⅔BY3⇌ BXY2 among all the boron trihalides have been examined by 11B n.m.r. spectroscopy in solvents methylcyclohexane and 1,1-dichloroethane at 33·5 °C; variable temperature studies ha